RICT 2016

Interfacing Chemical Biology and Drug Discovery

52nd International Conference on Medicinal Chemistry
52èmes Rencontres Internationales de Chimie Thérapeutique

 Caen, Normandy, France    July 6-8, 2016

Plenary Speakers

Prof. Jean-Daniel BRION
Paul Ehrlich Prize Lecture
Trip in Drug Discovery (PL01)
Dr Alan BROWN
The Discovery and Optimization of Benzimidzoles as Selective NAV1.8 Blockers for the Treatment of Pain (PL06)
Dr Pascal FURET
Conquering the p53-MDM2 Protein-Protein Interaction Target at Novartis (PL21)
Dr Mike HANN
Towards an Understanding of Cellular Drug Efficiency as a Way to Control Molecular Obesity (PL20)
Dr Michael HENNIG
Advances in Structure Based Drug Discovery of Membrane Protein Targets (PL14)
Dr James R. HENRY
Discovery of the Type II Kinase Inhibitor LY3009120; a Pan-RAF Inhibitor Showing Minimal Paradoxical Activation and Anti-Cancer Activity Against BRAF or RAS Mutant Tumor Cells (PL22)
Dr Jan HOFLACK
Nanocyclix: a Chemical Biology Approach for Next Generation Kinase Inhibitors (PL08)
Dr Eva JAKAB-TOTH
Molecular Imaging Agents Based on Lanthanide Complexes (PL17)
Dr Sven KÜHNERT
Optimization and Exploration of Bradykinin 1 Receptor Antagonists for Inflammation (PL07)
Prof. Bernhard KÜSTER
Human Proteomes – from Basic Biology to Understanding Drug Action (PL02)
Dr Oleg MELNYK
Protein Total Synthesis and the Challenge of Understanding MET Tyrosine Kinase Receptor Activation (PL11)
Prof. Adam NELSON
The Realisation of Activity-Directed Synthesis (PL19)
Dr Jean-Claude ORTUNO
Discovery of Selective Dopaminergic D3 Receptor Antagonists with Potent 5HT6 Affinity (PL10)
Dr Jean-Philippe PIN
Innovative Approaches to Control Metabotropic Glutamate Receptor Activity in the Brain (PL15)
Dr Santiago RIVERA
MT5-MMP, a New Potential Therapeutic Target in Alzheimer’s Disease (PL09)
Prof. Young-Ger SUH
Development of Novel Antiangiogenic Agents for the Treatment of Retinal Neovascularization via Integration of Chemistry and Biology (PL12)
Prof. Edward TATE
Protein Modification: from Chemical Biology to Drug Discovery (PL04)
Prof. Yasuteru URANO
Novel Fluorogenic Probes for In Vivo Imaging of Tiny Tumors and Super-Resolution Imaging in Living Cells (PL18)
Dr Michiel VAN GOOL
The Design of mGluR Modulators for CNS Disorders (PL16)
Dr Bruno VILLOUTREIX
Design of Chemical Probes Acting on Emerging Targets Assisted by Online Computational Tools (PL13)
Dr Alain WAGNER
Pierre Fabre Award for Therapeutic Innovation
A Scien-trepreneur Journey From Digital to In-vivo Organic Chemistry (PL23)
Dr Minoru YOSHIDA
A Role of SIRT2 in Cellular Response to Environmental Signals (PL05)
Dr Andrew ZHANG
Target Deconvolution Efforts Around Wnt Pathway Screen Reveal Parallel Mechanisms of Action for 1,2,3-Thiadiazole-5-Carboxamide Series (PL03)
 

Keynote Speakers

Dr Céline CANO
Development of Potent Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) (KL03)
Dr Sylvie CLAEYSEN
Original Serotonergic Multi-Target Directed Ligands against Alzheimer's Disease (KL02)
Dr Nicolas DESROY
Discovery of GLPG1690: a First-in-Class Autotaxin Inhibitor in Clinical Development for the Treatment of Idiopathic Pulmonary Fibrosis ( KL01)
Dr Steven DURRANT
Fragment-Based Design of ITK Inhibitors (KL06)
Dr Sébastien GOUIN
E.coli Anti-Adhesives, Potential Therapeutics for Crohn's Disease? (KL08)
Dr Andras KOTSCHY
Structure Guided Drug Discovery: Merits and Pitfalls Through the Example of Two Kinase Projects (KL04)
Dr Isabelle KRIMM
NMR for Chemical Biology and Drug Discovery (KL05)
Dr Françoise OCHSENBEIN
Inhibiting Chromatin Assembly by Targeting Histone Chaperones (KL07)